3:30 – 4:30 PM ET / 12:30 – 1:30 PM PT

SVB Leerink Liquid Biopsy and Oncology Dx Summit (April 6 – 7, 2021)

On Wednesday, April 7 at 3:30 PM ET, our CEO, Raj Krishnan, PhD, and CFO, Kevin Han will present an overview of the company’s next-generation liquid biopsy technology in development for early cancer detection during this two-day virtual event.

The CybeRx Series: Liquid Biopsy and Oncology Dx Summit will cover a number of current topics and key investment themes as precision oncology emerges as the standard of care and new markets open for liquid biopsy’s growing $50B+ estimated TAM. Leading KOLs and management teams address oncology diagnostics products from cancer screening to rapidly emerging indications in minimal residual disease (MRD) and the late stage and metastatic setting. The event will explore assay technologies, the strength of clinical evidence, key studies, pathways to adoption, and elements of reimbursements to commercial execution in this estimated $50B+ market.